X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice.

Hdl Handle:
http://hdl.handle.net/10147/128717
Title:
X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice.
Authors:
Mitchell, Jacqueline C; Ariff, Belall B; Yates, Darran M; Lau, Kwok-Fai; Perkinton, Michael S; Rogelj, Boris; Stephenson, John D; Miller, Christopher C J; McLoughlin, Declan M
Affiliation:
MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, London SE5 8AF, UK.
Citation:
X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. 2009, 18 (23):4492-500 Hum. Mol. Genet.
Journal:
Human molecular genetics
Issue Date:
1-Dec-2009
URI:
http://hdl.handle.net/10147/128717
DOI:
10.1093/hmg/ddp408
PubMed ID:
19744962
Abstract:
Increased production and deposition of amyloid beta-protein (Abeta) are believed to be key pathogenic events in Alzheimer's disease. As such, routes for lowering cerebral Abeta levels represent potential therapeutic targets for Alzheimer's disease. X11beta is a neuronal adaptor protein that binds to the intracellular domain of the amyloid precursor protein (APP). Overexpression of X11beta inhibits Abeta production in a number of experimental systems. However, whether these changes to APP processing and Abeta production induced by X11beta overexpression also induce beneficial effects to memory and synaptic plasticity are not known. We report here that X11beta-mediated reduction in cerebral Abeta is associated with normalization of both cognition and in vivo long-term potentiation in aged APPswe Tg2576 transgenic mice that model the amyloid pathology of Alzheimer's disease. Overexpression of X11beta itself has no detectable adverse effects upon mouse behaviour. These findings support the notion that modulation of X11beta function represents a therapeutic target for Abeta-mediated neuronal dysfunction in Alzheimer's disease.
Item Type:
Article
Language:
en
MeSH:
Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Female; Humans; Long-Term Potentiation; Male; Memory; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Tissue Proteins
ISSN:
1460-2083

Full metadata record

DC FieldValue Language
dc.contributor.authorMitchell, Jacqueline Cen
dc.contributor.authorAriff, Belall Ben
dc.contributor.authorYates, Darran Men
dc.contributor.authorLau, Kwok-Faien
dc.contributor.authorPerkinton, Michael Sen
dc.contributor.authorRogelj, Borisen
dc.contributor.authorStephenson, John Den
dc.contributor.authorMiller, Christopher C Jen
dc.contributor.authorMcLoughlin, Declan Men
dc.date.accessioned2011-04-27T09:19:17Z-
dc.date.available2011-04-27T09:19:17Z-
dc.date.issued2009-12-01-
dc.identifier.citationX11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. 2009, 18 (23):4492-500 Hum. Mol. Genet.en
dc.identifier.issn1460-2083-
dc.identifier.pmid19744962-
dc.identifier.doi10.1093/hmg/ddp408-
dc.identifier.urihttp://hdl.handle.net/10147/128717-
dc.description.abstractIncreased production and deposition of amyloid beta-protein (Abeta) are believed to be key pathogenic events in Alzheimer's disease. As such, routes for lowering cerebral Abeta levels represent potential therapeutic targets for Alzheimer's disease. X11beta is a neuronal adaptor protein that binds to the intracellular domain of the amyloid precursor protein (APP). Overexpression of X11beta inhibits Abeta production in a number of experimental systems. However, whether these changes to APP processing and Abeta production induced by X11beta overexpression also induce beneficial effects to memory and synaptic plasticity are not known. We report here that X11beta-mediated reduction in cerebral Abeta is associated with normalization of both cognition and in vivo long-term potentiation in aged APPswe Tg2576 transgenic mice that model the amyloid pathology of Alzheimer's disease. Overexpression of X11beta itself has no detectable adverse effects upon mouse behaviour. These findings support the notion that modulation of X11beta function represents a therapeutic target for Abeta-mediated neuronal dysfunction in Alzheimer's disease.-
dc.language.isoenen
dc.subject.meshAlzheimer Disease-
dc.subject.meshAmyloid beta-Peptides-
dc.subject.meshAmyloid beta-Protein Precursor-
dc.subject.meshAnimals-
dc.subject.meshBehavior, Animal-
dc.subject.meshCarrier Proteins-
dc.subject.meshDisease Models, Animal-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLong-Term Potentiation-
dc.subject.meshMale-
dc.subject.meshMemory-
dc.subject.meshMice-
dc.subject.meshMice, Inbred C57BL-
dc.subject.meshMice, Transgenic-
dc.subject.meshNerve Tissue Proteins-
dc.titleX11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice.en
dc.typeArticleen
dc.contributor.departmentMRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, London SE5 8AF, UK.en
dc.identifier.journalHuman molecular geneticsen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.